Car-t cell therapy for cd123-positive leukemia that has returned
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an experimental treatment using your own immune cells (called CAR-T cells) that are specially designed to find and destroy leukemia cells that have a specific marker called CD123. It is for people with acute myeloid leukemia (AML) that has not responded to treatment or has returned, and who have limited other options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have acute myeloid leukemia (AML) that is CD123 positive.
- Your leukemia has either not responded to standard treatment or has come back after remission.
- You are at least relatively well: able to do light activities, with an expected survival of at least 3 months.
- Your liver, kidney, and heart function are within acceptable limits (no severe organ damage).
- You have not had CAR-T cell therapy before and do not have certain infections (like HIV, active hepatitis B or C).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized cell therapy called CD33 CAR-T for people whose acute myeloid leukemia has come back or isn't responding to standard treatments. The goal is to see if it's safe and can help eliminate leukemia cells that carry the CD33 protein.
This study tests a new kind of immunotherapy called CAR-T cells that are engineered to find and attack leukemia cells carrying certain markers (CD33, CD123, or CLL-1). The treatment is given in two steps, aiming to kill cancer cells more effectively and possibly with fewer side effects.
This study tests a universal CAR-T cell therapy for acute myeloid leukemia (AML), a type of blood cancer. The treatment uses specially engineered immune cells to target leukemia cells with certain markers, and the trial aims to see if it is safe and effective for patients whose leukemia has not responded to standard treatments.
This trial tests a new type of immune cell therapy (CAR T cells) for people with acute myeloid leukemia (AML) that has come back or not gone away after treatment. The therapy is designed to find and attack leukemia cells that have a specific marker called CD371.
This trial tests a new treatment made from your own immune cells (CAR-T cells) that are designed to find and kill leukemia cells that have the FLT3 protein. It is for people with acute myeloid leukemia (AML) that has not responded to standard therapy or has returned after treatment.
This trial tests a new treatment that uses your own immune cells, modified in the lab to find and attack leukemia cells. It's for people with AML that has come back or hasn't responded to standard treatment, and it may be followed by a stem cell transplant to help prevent the cancer from returning.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.